-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Reviva Pharmaceuticals Holdings, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2020 to Q3 2024.
- Reviva Pharmaceuticals Holdings, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $0.000, a 100% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $10.2K, a 65.9% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. annual Income Tax Expense (Benefit) for 2023 was $16.9K, a 18.4% decline from 2022.
- Reviva Pharmaceuticals Holdings, Inc. annual Income Tax Expense (Benefit) for 2022 was $20.8K, a 246% increase from 2021.
- Reviva Pharmaceuticals Holdings, Inc. annual Income Tax Expense (Benefit) for 2021 was $6K, a 651% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)